Cargando…

FRI077 Efficacy Of Anti-obesity Medications Among Breast Cancer Survivors Taking Aromatase Inhibitors

Disclosure: S. Fansa: None. W. Ghusn: None. E. Tama: None. B. Nicolalde: None. D. Anazco: None. S. D'Andre: None. S. Faubion: None. C. Shufelt: None. A. Acosta: None. M.D. Hurtado: None. Background: Aromatase inhibitors (AIs) block estrogen synthesis and are used as adjuvant treatment for breas...

Descripción completa

Detalles Bibliográficos
Autores principales: Fansa, Sima, Ghusn, Wissam, Tama, Elif, Nicolalde, Bryan, Anazco, Diego, D'Andre, Stacy, Faubion, Stephanie, Shufelt, Chrisandra, Acosta, Andres, Hurtado, Maria D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10555325/
http://dx.doi.org/10.1210/jendso/bvad114.087
_version_ 1785116629959442432
author Fansa, Sima
Ghusn, Wissam
Tama, Elif
Nicolalde, Bryan
Anazco, Diego
D'Andre, Stacy
Faubion, Stephanie
Shufelt, Chrisandra
Acosta, Andres
Hurtado, Maria D
author_facet Fansa, Sima
Ghusn, Wissam
Tama, Elif
Nicolalde, Bryan
Anazco, Diego
D'Andre, Stacy
Faubion, Stephanie
Shufelt, Chrisandra
Acosta, Andres
Hurtado, Maria D
author_sort Fansa, Sima
collection PubMed
description Disclosure: S. Fansa: None. W. Ghusn: None. E. Tama: None. B. Nicolalde: None. D. Anazco: None. S. D'Andre: None. S. Faubion: None. C. Shufelt: None. A. Acosta: None. M.D. Hurtado: None. Background: Aromatase inhibitors (AIs) block estrogen synthesis and are used as adjuvant treatment for breast cancer. AIs are associated with weight gain that can lead to increased cardiometabolic risk, thereby affecting health and survivorship quality in these patients. The role of anti-obesity medications (AOMs) in patients using AIs has not been studied. We sought to investigate weight loss outcomes to AOMs in patients taking AIs for breast cancer treatment. Methods: This is a matched case-control retrospective cohort study of breast cancer survivors on AI using FDA-approved AOMs (AI/AOM group). We compared their weight loss outcomes with a group of female patients with obesity, without a history of breast cancer or AI use, on AOMs (AOM group). We matched patients by age and body mass index (BMI). Exclusion criteria: AOM initiation prior to AI therapy, ≤3 months of AOM use, history of bariatric surgery, active malignancy, or pregnancy. Primary endpoint: total body weight loss % (TBWL%) at 12 months. Secondary endpoints: TBWL% at 3 and 6 months and % of patients achieving categorical TBWL ≥5%, ≥10% and ≥15% at 12 months. We used Pearson χ2 and unpaired t-test to compare baseline characteristics and outcomes between groups, and univariate analyses to estimate the contribution of variables to TBWL% in the AI/AOM group. We present results as mean ± standard deviation. Results: We included 99 patients: 63 in the AI/AOM group (63.5±10 years, BMI 34.4±7.0 kg/m(2)) and 36 in the AOM group (60.4±8.7 years, BMI 36.3±6.9 kg/m(2)). Liraglutide, semaglutide and phentermine were the only AOMs used. There was no difference in the frequency of use of these three AOMs among both groups (p= 0.1). AI/AOM group had a lower TBWL% compared to the AOM group during follow-up: 3.7± 4.3% vs. 5.6 ± 4.1% (p= 0.03) at 3 months, 3.9± 4.3% vs. 9.5± 4.7% (p< 0.0001) at 6 months, and 5.2± 5.3% vs. 10.5± 6.8% (p< 0.0001) at 12 months. Although the AI/AOM group was more likely to use lower doses of AOMs (p= 0.0004), TBWL% differences persisted among groups at 12 months after adjusting for AOM dosing (p< 0.0001). There was no difference in nutritional and behavioral modification sessions among groups (p=0.06 and p=0.9, respectively). At 12 months, the percentage of patients achieving ≥5%, ≥10%, and ≥15% TBWL was greater in the AOM group compared to the AI/AOM group: ≥5% TBWL, 85.7% vs. 50.0% (p< 0.0001); ≥10%, 57.1 vs. 20.0% (p< 0.0001); and ≥15%, 28.6 vs. 5.0% (p< 0.0001); respectively. We found no predictors of TBWL% at 12 months in the AI/AOM group. Conclusion: Weight loss outcomes in breast cancer survivors on AIs taking AOMs are poorer compared to patients without breast cancer history and not taking AIs. Studies are needed to assess the mechanisms behind the different weight loss response to AOMs in women taking AIs, which we hypothesize may relate to AIs’ anti-estrogenic effect on lean and fat mass. Presentation: Friday, June 16, 2023
format Online
Article
Text
id pubmed-10555325
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-105553252023-10-06 FRI077 Efficacy Of Anti-obesity Medications Among Breast Cancer Survivors Taking Aromatase Inhibitors Fansa, Sima Ghusn, Wissam Tama, Elif Nicolalde, Bryan Anazco, Diego D'Andre, Stacy Faubion, Stephanie Shufelt, Chrisandra Acosta, Andres Hurtado, Maria D J Endocr Soc Adipose Tissue, Appetite, & Obesity Disclosure: S. Fansa: None. W. Ghusn: None. E. Tama: None. B. Nicolalde: None. D. Anazco: None. S. D'Andre: None. S. Faubion: None. C. Shufelt: None. A. Acosta: None. M.D. Hurtado: None. Background: Aromatase inhibitors (AIs) block estrogen synthesis and are used as adjuvant treatment for breast cancer. AIs are associated with weight gain that can lead to increased cardiometabolic risk, thereby affecting health and survivorship quality in these patients. The role of anti-obesity medications (AOMs) in patients using AIs has not been studied. We sought to investigate weight loss outcomes to AOMs in patients taking AIs for breast cancer treatment. Methods: This is a matched case-control retrospective cohort study of breast cancer survivors on AI using FDA-approved AOMs (AI/AOM group). We compared their weight loss outcomes with a group of female patients with obesity, without a history of breast cancer or AI use, on AOMs (AOM group). We matched patients by age and body mass index (BMI). Exclusion criteria: AOM initiation prior to AI therapy, ≤3 months of AOM use, history of bariatric surgery, active malignancy, or pregnancy. Primary endpoint: total body weight loss % (TBWL%) at 12 months. Secondary endpoints: TBWL% at 3 and 6 months and % of patients achieving categorical TBWL ≥5%, ≥10% and ≥15% at 12 months. We used Pearson χ2 and unpaired t-test to compare baseline characteristics and outcomes between groups, and univariate analyses to estimate the contribution of variables to TBWL% in the AI/AOM group. We present results as mean ± standard deviation. Results: We included 99 patients: 63 in the AI/AOM group (63.5±10 years, BMI 34.4±7.0 kg/m(2)) and 36 in the AOM group (60.4±8.7 years, BMI 36.3±6.9 kg/m(2)). Liraglutide, semaglutide and phentermine were the only AOMs used. There was no difference in the frequency of use of these three AOMs among both groups (p= 0.1). AI/AOM group had a lower TBWL% compared to the AOM group during follow-up: 3.7± 4.3% vs. 5.6 ± 4.1% (p= 0.03) at 3 months, 3.9± 4.3% vs. 9.5± 4.7% (p< 0.0001) at 6 months, and 5.2± 5.3% vs. 10.5± 6.8% (p< 0.0001) at 12 months. Although the AI/AOM group was more likely to use lower doses of AOMs (p= 0.0004), TBWL% differences persisted among groups at 12 months after adjusting for AOM dosing (p< 0.0001). There was no difference in nutritional and behavioral modification sessions among groups (p=0.06 and p=0.9, respectively). At 12 months, the percentage of patients achieving ≥5%, ≥10%, and ≥15% TBWL was greater in the AOM group compared to the AI/AOM group: ≥5% TBWL, 85.7% vs. 50.0% (p< 0.0001); ≥10%, 57.1 vs. 20.0% (p< 0.0001); and ≥15%, 28.6 vs. 5.0% (p< 0.0001); respectively. We found no predictors of TBWL% at 12 months in the AI/AOM group. Conclusion: Weight loss outcomes in breast cancer survivors on AIs taking AOMs are poorer compared to patients without breast cancer history and not taking AIs. Studies are needed to assess the mechanisms behind the different weight loss response to AOMs in women taking AIs, which we hypothesize may relate to AIs’ anti-estrogenic effect on lean and fat mass. Presentation: Friday, June 16, 2023 Oxford University Press 2023-10-05 /pmc/articles/PMC10555325/ http://dx.doi.org/10.1210/jendso/bvad114.087 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of the Endocrine Society. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Adipose Tissue, Appetite, & Obesity
Fansa, Sima
Ghusn, Wissam
Tama, Elif
Nicolalde, Bryan
Anazco, Diego
D'Andre, Stacy
Faubion, Stephanie
Shufelt, Chrisandra
Acosta, Andres
Hurtado, Maria D
FRI077 Efficacy Of Anti-obesity Medications Among Breast Cancer Survivors Taking Aromatase Inhibitors
title FRI077 Efficacy Of Anti-obesity Medications Among Breast Cancer Survivors Taking Aromatase Inhibitors
title_full FRI077 Efficacy Of Anti-obesity Medications Among Breast Cancer Survivors Taking Aromatase Inhibitors
title_fullStr FRI077 Efficacy Of Anti-obesity Medications Among Breast Cancer Survivors Taking Aromatase Inhibitors
title_full_unstemmed FRI077 Efficacy Of Anti-obesity Medications Among Breast Cancer Survivors Taking Aromatase Inhibitors
title_short FRI077 Efficacy Of Anti-obesity Medications Among Breast Cancer Survivors Taking Aromatase Inhibitors
title_sort fri077 efficacy of anti-obesity medications among breast cancer survivors taking aromatase inhibitors
topic Adipose Tissue, Appetite, & Obesity
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10555325/
http://dx.doi.org/10.1210/jendso/bvad114.087
work_keys_str_mv AT fansasima fri077efficacyofantiobesitymedicationsamongbreastcancersurvivorstakingaromataseinhibitors
AT ghusnwissam fri077efficacyofantiobesitymedicationsamongbreastcancersurvivorstakingaromataseinhibitors
AT tamaelif fri077efficacyofantiobesitymedicationsamongbreastcancersurvivorstakingaromataseinhibitors
AT nicolaldebryan fri077efficacyofantiobesitymedicationsamongbreastcancersurvivorstakingaromataseinhibitors
AT anazcodiego fri077efficacyofantiobesitymedicationsamongbreastcancersurvivorstakingaromataseinhibitors
AT dandrestacy fri077efficacyofantiobesitymedicationsamongbreastcancersurvivorstakingaromataseinhibitors
AT faubionstephanie fri077efficacyofantiobesitymedicationsamongbreastcancersurvivorstakingaromataseinhibitors
AT shufeltchrisandra fri077efficacyofantiobesitymedicationsamongbreastcancersurvivorstakingaromataseinhibitors
AT acostaandres fri077efficacyofantiobesitymedicationsamongbreastcancersurvivorstakingaromataseinhibitors
AT hurtadomariad fri077efficacyofantiobesitymedicationsamongbreastcancersurvivorstakingaromataseinhibitors